Senate ‘Innovation’ Bill Being Narrowed With Year-End Committee Passage In Mind
This article was originally published in The Pink Sheet Daily
Executive Summary
Counterpart to House Cures bill likely to focus on ‘big buckets’ of issues, including new approval pathway for antibiotics, reforms at NIH and biomarker development.
You may also be interested in...
Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard
CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.